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Introduction
The identification of biological markers heralding a pathological condition represents a major challenge in clinical proteomics. In this context, body fluids are a particularly interesting material source since their collection is minimally invasive compared to tissue biopsies. Indeed, in the discovery phase, the selection of a fluid in close proximity to a diseased-organ may increase the probability of finding a biomarker originating from a pathological tissue. In that respect, cerebrospinal fluid (CSF), which is in the closest contact with the brain, represents a useful reservoir of potential clinically relevant biomarkers for neurological diseases. Although acquisition of CSF via lumbar puncture is an invasive procedure, it is less invasive and more readily obtainable than a brain biopsy.
CSF has several functions, including buoyancy, protection of the brain to pressure gradients, transport of active biological substances for normal maintenance of the brain and excretion of toxic and waste substances (1, 2) . It surrounds the exterior of the central nervous system, filling also the four large ventricular cavities inside the brain, the spinal canal, and subarachnoid spaces. CSF is produced mainly in the choroid plexus, a structure present in the four ventricles, consisting of a single layer of epithelial cells surrounding a core of connective tissue and blood capillaries. These epithelial cells have tight junctions on the side facing the ventricle, which prevent the majority of blood substances from crossing the cell layer into the CSF and form what is known as the blood-CSF barrier. They produce CSF through a secretory process, based on active ion transport mechanisms that allows to maintain a constant ionic composition in the CSF and thus creates a stable ionic environment for the brain, independent of plasma ion concentration that can fluctuate significantly (3) . The protein content of the CSF produced in the choroid plexus originates mainly from blood proteins, which slowly cross the epithelial layer by a diffusion mechanism dependent on molecular size (1, 4) . Due to the presence of this barrier, however, the final protein concentration in CSF is around 200 times lower than in plasma. Some CSF proteins, on the other hand, are known to be synthesized and actively secreted by the epithelial cells of the choroid plexus, such as transthyretin or cystatin C (5).
In addition, a small amount of the CSF is not produced by the choroid plexus but originates from the extracellular fluid (ECF) that fills the extracellular space of the brain. This ECF is connected with the CFS via the perivascular space also known as Virchow-Robin space.
Indeed CSF also extends into the sulci and the depth of the cerebral cortex along the blood vessels in these perivascular spaces in which small molecules diffuse freely. ECF also flows into the ventricles by crossing the ependyma cells barrier between brain and CSF.
ECF carries proteins derived directly from the brain, which have been estimated to represent about 20% of the final CSF protein content (6) . Therefore there is a continuous movement of metabolites from deep parenchyma to cortical subarachnoid space and ventricular system. In that respect, CSF is also a biochemical window into the brain and constitutes an interesting source of potential neurological biomarkers.
Protein analysis in CSF has been actively performed during the past years in order to discover species relevant to a disease. Many validated clinical assays, each directed towards a particular protein and mostly based on antibody detection methods, have been developed to investigate protein candidates as potential markers of several pathologies.
These focused measurements [reviewed in (1) ] allowed a precise quantification of the selected proteins in CSF, and have shown that the dynamic range of protein concentrations spans at least 8 orders of magnitude between the most abundant protein (albumin at 130-350mg/L, representing alone around 45% of CSF protein content) and the lowest detected proteins in such assays in the ng/L range. This very large dynamic range represents, as for other body fluids, a major analytical challenge, and has largely hampered comprehensive studies aiming at global CSF proteomics characterization. The first studies were based on 2D-gels, which provided a useful tool to establish CSF maps, analyze protein modifications, and perform differential profiling (7) (8) (9) (10) . However, the relatively low dynamic range of the technique has usually limited the total number of detectable unique proteins to around 40 abundant species. Liquid nanochromatography / mass spectrometry (nanoLC-MS) based technologies allowed a significant increase of this number during the past few years, and different studies reported several hundreds of unique proteins confidently identified in CSF (11) (12) (13) (14) . To reach this number, extensive sample fractionation was usually applied at the protein or peptide level, in order to lower the concentration dynamic range of each individual fraction, as well as to increase the MS/MS sequencing time and analytical coverage of the sample. Most of these studies, however, remained largely qualitative, or restricted to the quantitative differential analysis of a small number of isotopically labeled samples. Only recently, the development of label-free approaches, based on the direct comparison of MS peptide signals across different nanoLC-MS runs using appropriate bioinformatic tools, has opened the way to the quantitative profiling of large series of patient samples for clinical studies with mass spectrometry techniques (15) . Thanks to the high resolution of recent mass spectrometers, such strategies seem now more accurate and promising for fluids proteomic profiling. However, a compromise has still to be found between a labor-intensive prefractionation of the samples and the number of patients included in the study, which should be ideally high for statistical significance.
Here, we performed a proteomic characterization of CSF using the combinatorial peptide ligand library technology, which has been described recently as an efficient approach to decrease the concentration dynamic range of complex protein mixtures (16) (17) (18) (19) . This method is based on the treatment of the sample with combinatorial libraries of peptide ligands bound to porous beads. Each bead contains a unique hexapeptide ligand distributed throughout its porous structure, and any protein in the starting material can theoretically interact with one or a few beads among the wide diversity (10-20 6 ) of ligand beads from the library. Once the most abundant protein species have saturated their binding sites, the remaining molecules are washed away in the flowthrough, while minor protein species are progressively enriched on their corresponding beads. This strategy has been efficiently applied to capture a very large population of previously undetected proteins in several types of samples such as urine (20) , serum (21), platelets (22) , and we used it recently for the extensive characterization of the red blood cell proteome (23) . Using a large pool of CSF from different sources, this method, associated with fractionation and nanoLC-MS/MS analysis, allowed here the detection of more than a thousand proteins in CSF.
Moreover, we evaluated several technical features relevant for its use in clinical studies, such as the conservation of relative quantitative information among parallel sample treatments, and the applicability on low CSF volumes typically obtained from lumbar puncture. We found that the miniaturized protocol is efficient and reproducible, and allows a significant increase of the number of quantified proteins in the peptide library-treated, but unfractionated sample. It could thus offer an interesting alternative for the rapid and indepth profiling of large series of CSF patient samples, avoiding the use of extensive prefractionation operations. It provides one of the first clinical compatible proteomic strategies targeting the deep proteome for CSF biomarker discovery, which should be a crucial biomedical issue for the exploration and management of brain diseases. For the large CSF study (treatment on 1mL ligand beads columns), 1290 ml of CSF were gathered from a pool of 250 patients (Pool 1). Most of the patients underwent a lumbar puncture in the context of headache and/or suspicion of a neurological disease not confirmed by RMI and CSF study (n=199). Volumes of samples obtained from these patients were 0.2 ml (n=100) or 0.5 ml (n=99). Another group of patients suffered from hydrocephalus, i.e. excess of CSF (n=49), and a tap test was performed in order to withdraw CSF via lumbar puncture. Volumes of the samples obtained in this way were 0.5 ml (n=1), 1ml (n=8), 3ml (n=30), 6ml (n=5) and 12ml (n=5). In addition, large volumes were obtained for samples collected using an overnight CSF drainage protocol for two patients suffering from hydrocephalus (108 ml, 150ml, 425 ml, and 350 ml). All samples came from the CSF discard after biochemical evaluation. For the assays on low volumes of beads, another pool of CSF samples was used (Pool 2), from 40 patients suffering from headache and investigated by lumbar puncture for a potential neurological disease not confirmed by RMI and CSF study. Volume of samples collected in this way was 0.5 ml per individual. In every case, we checked the absence of cellular abnormalities in CSF. We also checked the absence of an increased total proteomic content to eliminate pathologies with inflammatory reaction as well as blood-brain barrier abnormalities. Infectious diseases, as well as tumor formations and meningitis were eliminated. All samples were taken with the informed consent of the patients and were frozen immediately after clinical laboratory analysis.
Materials and Methods

Materials
Treatment of CSF proteins with hexapeptide ligand libraries
About 1290 ml of frozen pooled human CSF (CSF Pool1, 0.42 mg/mL protein concentration) was thawed at 4°C, added with two tablets of protease inhibitor cocktail and dialyzed against 50 mM ammonium bicarbonate overnight at +4°C. The dialyzed material was then centrifuged at 5000 g at 4°C for 30 minutes to obtain a clear protein solution and 
1D SDS-PAGE fractionation and nanoLC-MS/MS analysis of CSF proteins
One hundred and fifty µg of each elution fraction from the two library columns, as well as 150 µg of the initial non-treated human CSF, and 150µg of the flowthrough were diluted in The peptides mixtures were analyzed by nanoLC-MS/MS using an Ultimate3000 system 
Treatment of CSF samples on small volumes of peptide library beads
A pooled CSF sample of 20 mL (CSF Pool 2) was divided into 2 mL aliquots which were added to either 5 µL (four replicates) or 2 µL (four replicates) of PBS-equilibrated ProteoMiner beads in 2 mL centrifugation tubes. The CSF-beads suspensions were gently stirred at 4°C for 5 hours, then the beads were collected by centrifugation and washed twice with PBS. The proteins captured by the beads were eluted by addition of 15 µL of Laemmli sample buffer for electrophoresis and boiling 2 minutes at 95°C. Proteins were loaded on a 1D SDS-PAGE, and the whole protein mixture was concentrated into a unique gel band.
Tryptic peptides were prepared and analyzed in one nanoLC-MS/MS run as described above. For comparison, an aliquot of crude CSF (10µL, Pool 2) was prepared, digested, and analyzed in the same way.
Database Search and Data Analysis
The amino acids and with a Mascot score higher than the identity threshold at p=0.001 (99.9% probability), or at least two top ranking peptides each of minimal length of 5 amino acids and with a Mascot score higher than the identity threshold at p=0.05 (95% probability). In order to calculate the False Discovery Rate (FDR), the search was performed using the "decoy" option in Mascot, and MFPaQ used the same criteria to validate decoy and target hits. The FDR was calculated at the protein level (FDR = number of validated decoy hits / (number of validated target hits + number of validated decoy hits) x 100), and using the 
Label-free quantification
Quantification of proteins was performed using the label-free module implemented in the These mean values were calculated from an arithmetic averaging of the ratios, after applying a transformation to the asymmetric distribution of ratio values, in order to make it symmetric and centered around zero: (x-1) for ratios higher than one, and 
Results
Treatment of a large volume of pooled CSF samples with peptide libraries
In order to assess the efficiency of ProteoMiner treatment on CSF, an extensive proteomic study was performed using an experimental scheme previously described for other biological fluids (22, 23) (Figure 1 ). The sample was loaded on a sequence of two columns containing two different peptide ligand libraries, one composed of an amino-terminal collection of hexapeptides synthesized by combinatorial chemistry (NH 2 -Library), and the other one containing the same peptides in which the N-terminus has been modified to a carboxylate group (COOH-Library). The use of this second library has been shown before to be beneficial for capturing different species present in the sample compared to the NH 2 -Library, and for finally increasing the number of identified proteins (22, 23) . Moreover, in order to optimize the number of protein species captured by both combinatorial libraries, a high diversity of hexapeptide ligands is typically used to treat the samples. Thus, a volume of 1mL of ligand beads was used here in each column, as described in previous reports. As a large overloading of total beads capacity has to be performed to saturate abundant proteins and obtain a sufficient enrichment of low abundance species, large protein amounts are generally necessary when using this classical protocol. This was achieved in In order to evaluate the origin and function of the proteins revealed by the treatment, we classified the global list of protein groups identified in the study according to their Gene
Ontology terms using the GoMiner software. An example of a subclass of proteins of probable neural origin, associated with the GO term "neurogenesis", is shown in Table I .
Proteins are ranked by decreasing abundance (reflected by their total number of MS/MS counts), and those identified only after ProteoMiner treatment are displayed in grey (no protein specific from the crude material was present in this category). It clearly appears that the newly identified species are mostly low-abundance proteins, and many of them are involved in very specific neuronal functions such as control of axonal extension and dendrite outgrowth. This is for example the case for Semaphorin-3B, Meteorin, and also for proteins of the SLIT-RK family, which have been shown before to be overexpressed in some astrocytic brain tumors (25) . This data indicate that the treatment of CSF with the peptide libraries is able to unmask minor components originating from brain, which could constitute biologically relevant biomarkers, and that its use could be interesting for clinical studies on CSF.
Assessment of the saturation of peptide library beads for highly concentrated proteins
As the very principle of this strategy is to modify the concentration of the proteins in the starting material, its potential use for quantitative proteomic profiling studies on CSF remained to be assessed. We have previously performed quantitative experiments using 
Label-free quantification of proteins in CSF samples using the MFPaQ software
In order to evaluate the quantitative reproducibility of the peptide library treatment on a more global scale, a bioinformatic tool able to automatically extract the MS signal of all detected peptides was necessary. We previously described the MFPaQ software, which was designed to parse and validate protein identifications from Mascot result files, and quantify the identified proteins when using isotopic labeling strategies such as ICAT, SILAC, or N14/N15 labeling (26, 27) . The quantification module of this software starts from validated peptides lists and uses the m/z value and retention time associated to peptide ions (retrieved from Mascot result files), to extract the XIC signal of these ions in the corresponding raw files. In the case of isotopic labeling strategies, if only one member of the light/heavy peptide pair is identified by MS/MS, the software calculates the theoretical m/z value of its co-peptide and extracts its XIC signal in the same MS survey scans, as the two peptides are expected to co-elute in the same run. In MFPaQ version 4.0, the quantification module was upgraded so that it could handle label-free quantification using a similar approach. Thus, it was used here to extract the XIC signal for the same m/z value in two or several LC-MS/MS runs, corresponding to the same unlabeled peptide detected in different parallel analyses.
In order to assess the accuracy of the bioinformatic label-free quantification, and the technical reproducibility of the MS measurement, replicate analyses were performed on either crude CSF or ProteoMiner-treated CSF (first eluate from the NH 2 -Library), and identified proteins were quantified using this tool (Figure 1 ). For these assays, the samples were not fractionated, and the whole protein mixture was digested and analyzed in one LC-MS/MS run. As shown in Figure 4A , the reproducibility of the nanoLC-MS runs on the 
Efficiency and reproducibility of the ProteoMiner treatment on low CSF volumes
The experiment described above, designed to provide an extensive and qualitative characterization of the CSF proteome, was performed by treating a large volume of biological fluid on 1 mL peptide bead columns containing a very large panel of the two peptide ligand libraries. Moreover, differential elutions were performed, as well as extensive fractionation of each eluate on a 1D gel to reach a better analytical coverage of the sample.
Clearly, such an experimental scheme cannot be applied for routine clinical studies. A lumbar puncture typically yields only 1 to 2 mL of CSF, and due to the very low protein concentration in this fluid, this corresponds to less than 1mg of material. With such amounts, the beads volume must be decreased to only a few microliters in order to keep a reasonable overloading ratio of starting material versus beads capacity (about 10 mg/mL).
Moreover, if the aim of the study is to profile in a reproducible way large numbers of CSF patient samples, fractionation will be very difficult to implement. Thus, we miniaturized the treatment protocol to be compatible with such clinical application model. A pooled CSF sample was prepared from several lumbar punctures (CSF Pool 2), and 2 mL aliquots were Coefficients of variation for the quantified peptides on this population of proteins were only slightly higher (10.4% and 12.4% respectively for the 5 µL and 2 µL treatment), indicating that the quantification remained fairly accurate even on lower abundance proteins.
Together, this data indicates that the miniaturized protocol is efficient and reproducible, and that several hundred proteins can be accurately quantified in 2 hour-long analytical runs by using this treatment on low CSF volumes.
Discussion
In this study, we tried to evaluate the benefits of combinatorial peptide libraries for showed a relatively high number of specific proteins, not found in any of the two other ones.
In the case of the present study, 564 protein groups not reported in the previous publications were identified, most of them found thanks to the sample treatment with peptide libraries. Many reasons may account for the significant difference in protein identifications between these investigations, related either to the analytical techniques used, or to the CSF sample itself. Indeed, due to the depth and diversity of the CSF proteome, none of the list is probably exhaustive, and different fractionation methods or sample treatments may give access to separate categories of proteins. In this respect, the application of selective affinity purification methods (e.g. glycoprotein capture or ICAT labeling) versus more general enrichment strategies such as combinatorial peptide ligand libraries likely resulted in the detection of different low-abundance species. On the other hand, the molecular composition of CSF is highly dynamic and may vary significantly due to individual phenotype fluctuations, age of the patients, sample collection (lumbar puncture versus ventricular withdrawal), volume of CSF extracted, pathologies, and CSF bulk flow rate. In particular, the level of blood-derived proteins in CSF is highly dependent on blood-CSF barrier function and dysfunction. Moving from the concept of a morphological blood-CSF "leakage" model, this barrier function is now more widely interpreted using a model connecting molecular flux of blood proteins with CSF flow rate (4, 32) . Basically, the CSF flow rate is considered as the main factor modulating protein concentration in the fluid, and a reduced flow rate is for example sufficient to explain the non-linear increase of bloodderived CSF protein concentrations measured in neurological diseases (33) . The variation of CSF flow rate with age and pathologies of the individuals will thus largely influence the relative concentrations of blood or brain derived proteins in the sample analyzed, and may largely account for the heterogeneity of CSF proteomic reports so far.
In an attempt to determine the portion of CSF proteome originating from blood, Zhougman appears from these numbers that a very large portion of the CSF proteome is constituted by intrinsic species that may not be derived from blood but rather from brain. On the other hand, it is usually described that only about 20% of the protein content of CSF is predominantly brain-derived (1, 6, 34) . This percentage relates however to total protein amounts, while the different qualitative proteomic studies evaluate the diversity of the CSF composition only in terms of protein numbers. In order to get a more precise description of the CSF proteome, we quantified the proteins identified in our study by extracting MS intensity signal for each identified peptide, and calculated for each protein a PAI (Protein Abundance Index) defined as the average MS signal response for its three most intense tryptic peptides (35) . When summed together, the PAI of the 175 proteins shared between the crude CSF list and the plasma list represent in fact around 75% of the total PAI sum, a
value close to what is generally described.
In spite of the high abundance of blood-derived proteins in CSF, the peptide library technology used here was found to be an efficient approach to unravel low-abundance brain species which could not be detected before sample treatment. Interestingly, in CSF from patients without any neurological disease, it permits the detection of proteins related to different cell compartments inside the brain and to different crucial metabolic pathways, sometimes known to be overexpressed in particular diseases. For example, among the proteins involved in neurogenesis displayed in Table 1 , many were identified only after CSF treatment. This is the case of Semaphorin3B and neuropilin-1 and 2, that play a role in axonal guidance and cell migration (36) (37) (38) . Detection of these proteins may be of particular interest when studying tumoral brain pathologies such as glioma, as they have been proposed to be involved in local invasion and migration of tumour cells, which are pivotal mechanisms in glioma progression (39, 40) . Similarly, the 14-3-3 eta isoform or the SLIT and NTRK-like protein 1, identified only in treated-CSF, have also been shown to be expressed in astrocytoma and glioma cells (25, 41) . Other classical brain markers were detected after peptide library treatment, such as Neuron-specific enolase (gamma enolase)
or the astrocytic protein S100B, which are released in the CSF following brain cell degradation and are often used to detect pathologies involving brain damage such as
Creutzfeldt-Jakob disease (42) In addition to these spike experiments, reproducibility of the technology was checked on the global population of proteins detected by nanoLC-MS analysis, using the label-free quantification module of the MFPaQ software. Reproducibility assays were performed with a miniaturized protocol, applicable to real clinical CSF samples. Indeed, due to the high dilution of CSF proteins, and to the low volumes of fluid usually available after lumbar puncture, the total protein amount contained in such samples is quite low, which necessitates performing the treatment on very low volumes of beads. The use of small volumes of peptide ligand beads raises an important concern, which is to assess the effect of a large undersampling of the peptide library on both the efficiency and the reproducibility of the method. Indeed, the library is a pool of beads bearing each a unique, specific ligand, and due to the diameter of the beads, the total volume of resin necessary to have a statistical representation of almost all the hexapeptide ligands has been estimated to be around a few mL (56) . Thus, when very small volumes of beads are taken out of the bulk, the final number of peptide ligands is much smaller than the total number of library diversomers, and in addition, the population of ligands sampled out for each experiment is variable. We show here that this had no major effect on the efficiency of the treatment. Ideally, a proteomic analytical method aiming at biomarker discovery should allow i) the detection of a large number of proteins, ii) their quantification with a good accuracy, and iii)
analysis of a large number of patient samples to provide statistically significant results.
However, a compromise has to be found between these requirements. For example, although extensive fractionation by 1D gel of a sample represents a useful way to identify a high number of species by MS/MS, it may not be an ideal solution to quantitatively profile large series of samples in a reproducible way. Conversely, while SELDI-TOF is a wellsuited tool to perform this later task, it may give only access to the profiling of a limited number of low-mass proteins. NanoLC-MS profiling of enzymatically digested proteins, using label-free quantification on high-resolution mass spectrometers, may provide alternative solutions. These strategies have already been used to identify new biomarkers in CSF, with good results (15, 58) . In such approaches, very limited or no fractionation at all is usually performed on the sample, due to the large number of analyses that must be performed (number of patients and technical replicates), and the intrinsic variability that may be introduced by the fractionation procedure itself. In such an experimental scheme, where the protein mixture is analyzed in one run, the treatment of CSF samples on peptide ligand library was shown to be particularly useful to lower the dynamic range of the protein mixture and increase the number of detected and quantified protein, without fractionating the sample. Moreover, the MFPaQ software (available at http://mfpaq.sourceforge.net) was
shown to be an efficient tool to accurately quantify proteins in CSF. With the use of an identification database, previously built from the analysis of 20 fractions of the sample separated on a 1D SDS-PAGE, around 500 protein species could be mapped and successfully quantified in replicate nanoLC-MS/MS analyses of CSF aliquots treated on low volumes of beads. Clearly, the analytical coverage of the sample was not as large as in the first large-scale, extensive proteomic analysis, which yielded a final list of 1212 proteins.
However, it was obtained with an analytical time reduced by a factor 7, and the analysis was reproducible and potentially applicable to many more replicates. Moreover, the list of proteins detected using this strategy still contains many biologically relevant species derived from brain cells (e.g. the brain injury markers S100B and Neuronal-specific enolase, Glial fibrillary acidic protein, pentraxin-1 and 2, neuropilin-1 and 2, PARK7 DJ-1, SLITRK1,…), providing potentially interesting candidates in the perspective of biomarker discovery studies.
In conclusion, the analytical workflow presented here, using the miniaturized ProteoMiner protocol and the bioinformatic data processing method developed in MFPaQ, allowed to profile the CSF proteome with a reasonable depth (about 500 proteins quantified) in short analytical times (less than 2 hours per sample) and with good accuracy (CVs typically around 10% for replicate measurements). It could thus represent a useful approach for future clinical studies on CSF.
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